CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home About CADTH What We Do Programs and Services CADTH Reimbursement Review luspatercept
Back to Programs and Services

CADTH Reimbursement Review

luspatercept

Last Updated: December 23, 2020
Result type: Reports
Project Number: SR0670-000
Product Line: Reimbursement Review

Generic Name: luspatercept

Brand Name: TBC

Manufacturer: Celgene Inc., a Bristol Myers Squibb company

Therapeutic Area: Myelodysplastic syndromes-associated anemia

Indications: ​For the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions.

Manufacturer Requested Reimbursement Criteria1: ​For the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: December 23, 2020

Call for patient/clinician input closed: February 22, 2021

Anticipated Date: January 28, 2021

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback